Sphere Medical

www.spheremedical.com TICKER: SPHR     EXCHANGE: L

Sphere Medical develops and commercialises medical monitoring and diagnostic equipment. Its lead product, Proxima, provides near real-time analysis of blood gases, electrolytes, and metabolites at the patient's bedside within critical care.

LATEST REPORTS

 
CE Mark opens the door to commercialisation
Published: Sep 30 2016

 
On the cusp of commercialisation
Published: Sep 22 2016

 
First Belgian order for Proxima confirmed
Published: Aug 30 2016

 
CE Mark expected shortly, launch preparations on track
Published: Jul 21 2016

 
Worthy of further evaluation
Published: Feb 24 2016

The finalisation of Proxima 4's development phase opens the way for its commercialisation in Europe, with CE Marking expected mid-2016. The experience gained with Proxima 3 has provided valuable insights that should improve market traction. A launch employing the in-house sales team is expected before year-end but exploiting Proxima 4's potential will require a well-placed existing player. The identification of a suitable marketing partner is a critical next step, with initial discussions underway. Our three phase DCF-based model suggests a valuation of £14.4m, equivalent to 10.2p per share. 

ARCHIVE

Foreign buyers gorging on UK stocks

Document can be downloaded here: UK plc ‘going for a song’

Being a shareholder in a company that receives a juicy takeover offer is a marvellous feeling. Something that many fortunate investors have experienced over the past 3 years. Thanks to a spate of M&A bids by deep pocketed overseas buyers – partly triggered by the June 2016 Brexit result, which sent the £ tumbling and adversely affected the FTSE.

Consequently today, given this trend is unlikely to end anytime soon, we’ve highlighted 30 possible acquisition ideas in the attached research paper. Spilt equally between large and smallcap stocks – covering a broad selection of industries.

What’s more we believe most of these businesses are underpinned by strong fundamentals and substantial upside in the event of predatory interest.

According to Factset Mergerstat/BVR, the average bid premium paid for such deals between 2004-14 was 30% – with the figure trending upwards since the global financial crisis.

Happy investing. Published 27th August 2019